Declaration of competing interests

Editor
Martin Rossor
Deputy Editor
Mike Hanna

Associate Editors
Simon Fleminger
Didier Leys
Philip Scheltens
Peter Warnke
 

Updated 25the April 2007

Martin Rossor

The Editoris employed by University College London as Professor of Neurology and Chairman of Division of Neurology at the Institute of Neurology and also holds a Personal Chair in Clinical Neurology at Imperial College.

He is Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery at St Mary's Hospital NHS Trust and at The Hospital for Sick Children, Great Ormond Street.

From 2003, he has been in receipt of the following industry grants:

1999-04 - Novartis Pharmaceuticals UK Ltd

Investigation into delay to diagnosis of Alzheimer's Disease with Exelon (InDDEx)

1999-03 - GlaxoSmithKline Ltd
MIRIAD - Minimal interval resonance imaging in Alzheimer's Disease

2001-04 - Ingenix Pharmaceuticals
A multicentred, randomised, double blind, placebo controlled, parallel group study of 9600 and 4800 mg/day piracetam taken for 12 months by subjects suffering from Mild Cognitive Impairment

2001-02 - GlaxoSmithKline R&D
A study to identify surrogate and prognostic markers in Alzheimer's Disease

2001-03 - Elan Pharmaceuticals Inc/Wyeth Research UK Limited

A randomised double blind safety tolerability and pilot efficacy study of AN1792(QS-21) in patients with mild to moderate Alzheimer's Disease MRI Study

2001-04 - JANSSEN Pharmaceutica NV

GAL-INT-11 MRI Study

He has received honoraria for lectures or advisory boards attendance for:

• Elan Pharmaceuticals Inc
• Servier

He is a Vice President of the Alzheimer's Society, a Patron of the Dementia Relief Trust and of the Niemann-Pick Disease Group (UK). He is a member of The Court of Assistants of The Society of Apothecaries of London, and a member of Council of the Association of British Neurologists.

He is on the Editorial Board of Practical Neurology, Dementia and Geriatric Cognitive Disorders, Neurodegenerative Diseases, Brain Aging International Journal, Neuroscience Reviews and Dementia and Neuroscience Reviews.

Mike Hanna

Mike Hanna  has no competing interests.

Simon Fleminger

Simon Fleminger receives fees for consulting and funds for research from Blackheath Brain Injury Rehabilitation Centre

Is on the editorial boards of Cognitive Neuropsychiatry and Neuropsychological Rehabilitation

Didier Leys

Since 2004, Didier Leys has received grants for research, fees for consulting, speaking, attending advisory boards or steering committees from the following private pharmaceutical companies: Sanofi-Synthelabo, AstraZeneca, Servier, Bristol Myerrs Squibb, Boeringher Ingelheim and Lilly.

He has received public grants for research from the French Ministry of research and the EU and has acted as expert for public research grant applications in France, Belgium, The Netherlands, Germany and Switzerland, and for private grants in France and Italy. He was a member of the writing committee of the European recommendations for stroke management in 2004.

He is a member of the Editorial Board for both Stroke and CerebroVascular Diseases.

Philip Scheltens

Since 2004, Philip Scheltens has received grants for research from the following private pharmaceutical companies: Sanofi-Synthelabo, Servier, Novartis AG, Lundbeck and Jansen Research Foundation.

He has received public grants for research from the Dutch Ministry of Research (NWO) and the EU and has acted as expert for public research grant applications in the UK, Belgium, Germany, Sweden, Italy and the US.

Is on the board of Dementia and Book review editor of Alzheimer Disease and Associated Disorders.

Peter Warnke

Peter Warnke currently has industry grants from Xenova, Neopharm, Ark Therapeutics and Direct Therapeutics. He has public grants from Clatterbridge Cancer Research Trust, Walton Neuroscience Fund and Northwest Cancer Research.

He serves on the Steering Committee for the PRECISE-Trial and CEREPRO-Trial.